Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Eligibility Criteria

• 1. Be willing and able to provide a written Informed Consent Form ("ICF") for the Study.
• 2. Be \> 18 years of age on day of signing ICF.
• 3. Have histologically confirmed NMIBC CIS via biopsy with/without resected papillary disease (Ta, T1) (high grade) using the 2004 World Health Organization ("WHO") / International Society of Urologic Pathology classification system. The most recent cystoscopy / TURBT must have been performed within 12 weeks of the Study Treatment date to confirm: histology, grade and stage.
• 4. Intolerant to BCG or considered BCG-Unresponsive, which is at least one of the following:
• * At least five of six doses of an initial induction course, plus at least two of three doses of maintenance therapy, or
• * At least five of six doses of an initial induction course, plus at least two of six doses of a second induction course.
• 5. Are not candidates for cystectomy on medical grounds or refuse radical cystectomy.
• 6. Have an Eastern Cooperative Oncology Group ("ECOG") performance score of 0 to 2.
• 7. Have satisfactory bladder function. Ability to retain Study Drug for a minimum of 60 minutes.
• 8. Are available for the duration of the Study including follow-up (approximately 15 months).
• 9. Female patients of childbearing potential must have a negative Human Chorionic Gonadotropin ("HCG") pregnancy test taken during the screening visit and confirmed prior to the Study Treatment.
• 10. Female patients of childbearing potential must be willing to use 2 methods of birth control (i.e.: oral contraceptive, pills, diaphragm or condoms) or be surgically sterile, or abstain from heterosexual activity for two weeks after the Study Treatment. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \>1 year.
• 1. Past or current muscle invasive (i.e.: T2, T3, T4) or metastatic urothelial carcinoma.
• 2. Has concurrent extravesical (i.e.: urethra, ureter, renal pelvis, prostate or prostatic ducts) non-muscle invasive transitional cell carcinoma of the urothelium. (confirmed by staging to exclude extravesical disease, which may include radiological imaging and/or biopsy) within 3 months of enrollment:
• 3. Active gross hematuria.
• 4. Have a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer or localized prostate cancer under active surveillance with Gleason 6 disease. A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower Prostate-Specific Antigen ("PSA") undetectable for 2 years while off androgen deprivation therapy or no more than 2 consecutive rising PSAs.
• 5. Have a history or current evidence of any condition, therapy, surgery or laboratory abnormality that, in the opinion of the PI, might confound the results of the Study, interfere with the patient's participation in the Study, or is not in the best interest of the patient to participate.
• 6. Currently receiving treatment with a prohibited concomitant therapy (refer to 12.2.1, Prohibited Medications).
• 7. Participated in a study with an investigational agent or device within 1 month from the first dose of current Study treatment.
• 8. Prior treatment with an intravesical chemotherapeutic agent within 1 month of the first dose of current Study Drug, with the exception of a single perioperative dose of chemotherapy immediately post-TURBT (not considered treatment).
• 9. Have an active infection requiring systemic therapy, including active or intractable Urinary Tract Infection ("UTI"), not resolved prior to the procedure.
• 10. Has any contraindication to general or spinal anesthesia.
• 11. Is pregnant or breastfeeding within the projected duration of Study II, starting with the screening visit through to two weeks following the second Ruvidar® (TLD-1433) instillation.